Genzyme (NASDAQ: GENZ) announced that it has gained FDA approval for Renvela (sevelamer carbonate), a drug that helps keep blood levels of phosphorus from getting too high in patients on dialysis. The new drug is a next-generation version of a similar Genzyme drug approved in 1998.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
